Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Intangibles (2020 - 2025)

Cytek Biosciences' Intangibles history spans 6 years, with the latest figure at $16.8 million for Q4 2025.

  • For Q4 2025, Intangibles fell 16.43% year-over-year to $16.8 million; the TTM value through Dec 2025 reached $16.8 million, down 16.43%, while the annual FY2025 figure was $16.8 million, 16.43% down from the prior year.
  • Intangibles reached $16.8 million in Q4 2025 per CTKB's latest filing, down from $17.7 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $24.7 million in Q1 2023 to a low of $333000.0 in Q2 2021.
  • Average Intangibles over 5 years is $14.5 million, with a median of $18.6 million recorded in 2025.
  • Peak YoY movement for Intangibles: surged 1629.56% in 2021, then decreased 16.43% in 2025.
  • A 5-year view of Intangibles shows it stood at $4.7 million in 2021, then decreased by 8.61% to $4.3 million in 2022, then skyrocketed by 432.99% to $23.1 million in 2023, then fell by 12.81% to $20.1 million in 2024, then fell by 16.43% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Intangibles are $16.8 million (Q4 2025), $17.7 million (Q3 2025), and $18.6 million (Q2 2025).